Innate immunity is a built-in defense that quickly identifies bacteria and viruses and triggers inflammation. Until the 1990s, how immune cells recognized “enemies” was still unclear. Working with fruit flies, Hoffmann showed that mutants lacking the Toll gene could not survive fungal infection. In mice unresponsive to the sepsis-inducing substance LPS, Beutler pinpointed a mutation in the TLR4 gene. Toll and TLR4 detect conserved microbial molecules such as lipopolysaccharide or β-glucan, then activate NF-κB signaling. This results in cytokine release and the recruitment of neutrophils and macrophages to stop the infection. Their work established the idea of “pattern-recognition receptors” (PRRs) and accelerated research on vaccine adjuvants and autoinflammatory diseases.

Toll and Toll-like receptors (TLRs) are type-I transmembrane proteins with an extracellular leucine-rich-repeat domain and a cytosolic Toll/IL-1 receptor domain. Binding of pathogen-associated molecular patterns such as lipopolysaccharide, flagellin, or fungal β-glucan induces receptor dimerization and recruits adaptor proteins like MyD88 or TRIF. This activates IRAK and TRAF6, leading to the IKK complex activation, IκB degradation, and nuclear translocation of NF-κB, which initiates transcription of pro-inflammatory cytokines. Beutler’s positional cloning narrowed the Lps locus to a 2.6-Mb interval and identified a point mutation (P712H) in Tlr4 in LPS-resistant mouse strains. The Toll pathway discovery also demonstrated that embryonic patterning and immune signaling share homologous cascades in flies, evidencing deep evolutionary conservation. Functional TLR4 requires accessory molecules MD-2, CD14, and LBP; its over-activation drives septic shock. TLR agonists such as monophosphoryl-LPS are used as vaccine adjuvants, whereas TLR antagonists are being explored to treat inflammatory disorders. More than ten human TLRs are now characterized, and understanding their PAMP specificity and downstream signaling guides modern immunotherapy design.

After heterodimerizing with MD-2, TLR4 clamps lipid A of LPS, creating a symmetric dimer that re-orients its TIR domains to engage MyD88- and then TRIF-dependent adapters sequentially. The P712H mutation found in C3H/HeJ mice lies in the BB-loop of the TIR domain, disrupting TIR-TIR interactions and abolishing signaling. Downstream, IRAK4 phosphorylation is indispensable; human IRAK4-deficiency cases with pyogenic infections clinically validate pathway importance. Drosophila Toll is governed by the Spätzle protease cascade and regulates Cactus/IκB and Dorsal/Dif translocation, paralleling mammalian NF-κB control. Sequence and functional analyses of orphan receptors such as human TLR10 and mouse TLR11-13 have expanded understanding of non-self/self RNA sensing and host-pathogen co-evolution. High-resolution structural work shows agonist-dependent conformational shifts and π-stacking within TIR self-association domains as critical for signal propagation. To curb LPS-induced cytokine storms, inhibitors like TAK-242, Eritoran, and anti-CD14 antibodies have undergone clinical evaluation, yet effective sepsis therapy remains elusive. Conversely, TLR3/7/8/9 agonists activate dendritic cells in tumors and are being tested with checkpoint blockade to improve responses. Crosstalk among PRR networks, especially with the NLRP3 inflammasome and STING pathway, demands systems-level dissection. Toll/TLR research thus provides a cross-disciplinary platform accelerating the hunt for molecular targets in immune-homeostasis disorders.